Key Resources

Explore our library of presentations, brochures and relevant publications

Discover DefiniGEN

Download a short introduction to DefiniGEN, learn more about our company and how we can help accelerate and de-risk your drug discovery research.



Discover DefiniGEN

Case studies


Discover DefiniGEN

Alpha-1 Antitrypsin Deficiency

Learn more about how our CRISPR-derived A1AT cells can reproducibly recapitulate the disease phenotype in-a-dish, revealing increased polymeric alpha-1-antitrypsin formation and accumulation compared to their isogenic controls.


Screenshot 2024-05-17 131055

Opti-HEP Functionality

DefiniGEN’s proprietary differentiation protocols permit the large-scale generation of iPSC-derived hepatocytes (Opti-HEP) with field-leading purity and functionality. Importantly, Opti-HEP successfully recapitulate key aspects of disease pathophysiology across a wide range of conditions that affect different aspects of liver function.


Abridged case studies

Learn more about the key aspects and key data sets of our in-house models




Using iPSC-Derived Hepatocyte Models for Disease Modeling and Predictive Toxicology Screening

In this GEN webinar, our speakers will present new research into iPSC-derived hepatocyte models, how they compare to liver cancer cells lines and why they are a better model for large-scale preclinical drug studies. During the webinar, you’ll learn about DefiniGEN’s highly characterized iPSC-derived hepatocytes (Opti-HEP) and how they provide a sustainable in vitro platform for ADME and toxicology screening.


Discover how iPSC derived cells can be used to support the development of drug and gene therapies

In this webinar you will discover how iPSC derived cells can be used to advance the efficiency and efficacy of disease modeling. The webinar will cover topics including functionality, modeling disease phenotypes, therapeutic modalities and delivery and efficacy.


On-demand Webinar Graphic - iPSC derived cells_Ludovic Vallier_September_2023
DefiniGEN White Paper

White paper

In this white paper you will discover how human induced pluripotent stem cell derived hepatocyte-like cells (HLCs) have the potential to act as an ideal model for the study of liver diseases, combining the expansion capacity and phenotypic stability of hepatoma cell lines with the functionality and normal karyotype of primary hepatocytes.


Within the white paper you will also learn more about DefiniGEN’s iPSC-derived HLC platform which is capable of screening candidate therapeutics with high accuracy and reproducibility.


Advance your scientific discoveries with our disease model development and screening services.